Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Taiwan's TLC Completes $27 Million Secondary Offering

publication date: Oct 24, 2019

Taiwan Liposome Company (TLC) completed a $27.3 million secondary offering to advance its nanomedicine candidates for pain management, ophthalmology and oncology. The clinical-stage company uses three platforms to develop new drugs: LipAD™, a lipid-assembled drug delivery platform that controls onset speed and benefit duration; BioSeizer® which allows local sustained release of agents at a specific site; and NanoX™, a loading technology designed to increase active drug concentration while decreasing unwanted systemic exposure. More details....

Stock Symbols: (NSDQ: TLC; TWO: 4152)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.